PW 3101Alternative Names: PW3101
Latest Information Update: 10 Aug 2007
At a glance
- Originator Penwest Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
- 30 Nov 2002 Preregistration for Asthma in USA (PO)